Jubilant Pharmova Fact Sheet, Jubilant Pharmova Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Jubilant Pharmova Fact Sheet    (JUBOL)


WATCH NOW: India's Revival Urgent Broadcast (available till 11:59pm tonight)


Here is the latest financial fact sheet of Jubilant Pharmova. For more details, see the Jubilant Pharmova quarterly results and Jubilant Pharmova share price and chart. For a sector overview, read our pharmaceuticals sector report.

JUBILANT PHARMOVA Price History

Price Rs 726.3
Mkt Cap Rs m 115,677
Vol '000 9.5
P/E X 12.9
P/CF X 12.2
EPS (TTM) Rs 56.4
% ch % -2.0
No. of shares m 159.28
% ch week % 4.7
% ch 1-mth % -4.2
% ch 12-mth % 110.8
52 week H/L Rs 1,046.8/328.3
(As on Apr 15, 2021 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

JUBILANT PHARMOVA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
JUBILANT PHARMOVA  EQUITY SHARE DATA
High Rs2224558301,039898 
Low Rs116138294600618 
Sales per share (Unadj.) Rs365.7364.2376.3472.0572.0 
Earnings per share (Unadj.) Rs-3.627.136.939.836.2 
Diluted earnings per shareRs-3.627.136.139.836.2 
Cash flow per share (Unadj.) Rs14.448.855.665.959.5 
Dividends per share (Unadj.) Rs3.003.003.003.004.50 
Adj. dividends per shareRs3.003.002.933.004.50 
Dividend yield (eoy) %1.81.00.50.40.6 
Book value per share (Unadj.) Rs154.0182.6220.6256.6301.9 
Adj. book value per shareRs154.0182.7215.7256.6301.9 
Shares outstanding (eoy) m159.31159.31155.75159.28159.28 
Bonus/Rights/Conversions  --ESOPESOP- 
Price / Sales ratio x0.50.81.51.71.3 
Avg P/E ratio x-46.610.915.220.620.9 
P/CF ratio (eoy) x11.76.110.112.412.7 
Price / Book Value ratio x1.11.62.53.22.5 
Dividend payout %-82.811.18.17.512.4 
Avg Mkt Cap Rs m26,93147,23587,547130,530120,694 
No. of employees `0002.46.22.42.42.4 
Total wages/salary Rs m10,90311,26712,30915,55919,260 
Avg. sales/employee Rs Th24,387.89,384.324,535.130,861.438,120.6 
Avg. wages/employee Rs Th4,563.81,822.35,152.56,387.08,058.4 
Avg. net profit/employee Rs Th-241.7697.92,405.32,604.42,414.3 
JUBILANT PHARMOVA  INCOME DATA
Net Sales Rs m58,26258,02358,61475,17891,108 
Other income Rs m425136249400357 
Total revenues Rs m58,68758,16058,86375,57991,466 
Gross profit Rs m6,89312,77813,45315,18417,390 
Depreciation Rs m2,8803,4602,9144,1513,709 
Interest Rs m3,5533,7863,4112,8432,198 
Profit before tax Rs m8845,6697,3768,59111,840 
Minority Interest Rs m-1760000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-48117500-2,802 
Tax Rs m8051,5291,6302,2473,268 
Profit after tax Rs m-5784,3155,7466,3445,770 
Gross profit margin %11.822.023.020.219.1 
Effective tax rate %91.027.022.126.227.6 
Net profit margin %-1.07.49.88.46.3 
JUBILANT PHARMOVA  BALANCE SHEET DATA
Current assets Rs m27,14529,01329,48131,89845,848 
Current liabilities Rs m21,29225,14516,84020,04720,897 
Net working cap to sales %10.06.721.615.827.4 
Current ratio x1.31.21.81.62.2 
Inventory Days Days7776766857 
Debtors Days Days5158635551 
Net fixed assets Rs m55,07956,85058,90560,71565,498 
Share capital Rs m159159156156159 
"Free" reserves Rs m24,37628,93634,20540,71047,930 
Net worth Rs m24,53529,09634,36040,86548,089 
Long term debt Rs m36,91330,44035,05030,47842,429 
Total assets Rs m86,18889,47090,40796,176114,685 
Interest coverage x1.22.53.24.06.4 
Debt to equity ratio x1.51.01.00.70.9 
Sales to assets ratio x0.70.60.60.80.8 
Return on assets %3.59.110.19.66.9 
Return on equity %-2.414.816.715.512.0 
Return on capital %6.216.215.516.012.4 
Exports to sales %26.921.3000 
Imports to sales %17.714.6000 
Exports (fob) Rs m15,64812,339000 
Imports (cif) Rs m10,2898,475000 
Fx inflow Rs m15,78512,34410,88114,40212,422 
Fx outflow Rs m11,9689,4307,76212,04417,227 
Net fx Rs m3,8172,9143,1192,358-4,805 
JUBILANT PHARMOVA  CASH FLOW
From Operations Rs m 7,833 10,923 12,685 13,032 11,215 
From Investments Rs m -3,433 -3,265 -4,504 -6,177 -10,118 
From Financial Activity Rs m -5,027 -8,223 -6,859 -9,011 6,574 
Net Cashflow Rs m -819 -525 1,172 -2,123 7,612 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 45.6%
Foreign collaborators 3.5%
Indian inst/Mut Fund 8.7%
FIIs 21.2%
ADR/GDR 0.0%
Free float 21.1%
Shareholders 23,815
Pledged promoter(s) holding 15.9%
 

Company Information

REGD OFF Bhartiagram, Gajraula, Dist. Jyotiba Phoolay Nagar, U.P - 244 223
E-MAIL investors@jubl.com WEB www.jubl.com
TELEPHONE (0120) 436 1000 FAX (0120) 423 4895
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Alankit Assignments, Alankit House, 2E/21, Jhandewalan Extn., Delhi-55
AUDITOR K. N. Gutgutia & Co.
CHM: Shyam S. Bhartia COMP SEC: Lalit Jain YEAR OF INC: 1978 BSE CODE: 530019 FV (Rs): 1 DIV YIELD (%): 0.6

Read: JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   ALEMBIC  VENUS REMEDIES  PIRAMAL ENTERPRISES  ASTRAZENECA PHARMA  UNICHEM LAB  

Compare JUBILANT PHARMOVA With:   ALEMBIC  VENUS REMEDIES  PIRAMAL ENTERPRISES  ASTRAZENECA PHARMA  UNICHEM LAB  

Compare JUBILANT PHARMOVA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  




Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Views on news

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday (Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK JUBILANT PHARMOVA

  • Track your investment in JUBILANT PHARMOVA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT PHARMOVA

JUBILANT PHARMOVA 8-QTR ANALYSIS

COMPARE JUBILANT PHARMOVA WITH

MARKET STATS